Most Participants Recruited for Walvax mRNA COVID Vaccine Trial
China's Walvax Biotechnology has recruited most of the 28,000 participants needed for a large clinical trial of its mRNA COVID-19 vaccine candidate, a senior company official said on Thursday.
Reuters Health Information
source https://www.medscape.com/viewarticle/967396?src=rss
Reuters Health Information
source https://www.medscape.com/viewarticle/967396?src=rss
Comments
Post a Comment